Citius Oncology, Inc. ("Citius Oncology" or the "Company") , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today ...

ISOThrive Inc. today announced positive Phase 2 results for MHS-1031 treating NERD patients with incomplete response to ...

FDA approves VEPPANU (vepdegestrant), the first PROTAC protein degrader therapy, for ER+/HER2-, ESR1-mutated advanced breast ...

Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA ...

ZYNLONTA combo trials in r/r DLBCL, key LOTIS-5 data Q2 2026, strong ORR/CR, cash to 2028—read now. Click for this ADCT ...

Investigators developed and validated a deep learning-powered segmentation model to analyze inner retinal layers and improve ...

Immix Biopharma Inc. (NASDAQ:IMMX) is one of the best performing NASDAQ stocks according to Wall Street analysts.

The gene-editing drug is designed to treat patients with elevated low-density lipoprotein cholesterol or serum triglycerides.

Updated 12-month follow-up results may support regulatory progress for its lead oncology candidate. Cellectar Biosciences, ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

Proton-based cardiac radioablation may offer a less invasive treatment for patients with hard-to-treat ventricular ...

ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 monthsFDA-requested dataset with ...